{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:44:08Z","timestamp":1785386648921,"version":"3.55.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"DOI":"10.3389\/fchem.2020.00256","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T05:32:25Z","timestamp":1586928745000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Synthesis and Biological Evaluation of HDAC Inhibitors With a Novel Zinc Binding Group"],"prefix":"10.3389","volume":"8","author":[{"given":"Junquan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songsong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruili","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenghong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingrong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/1756283X16644247","article-title":"Epigenetic therapy in gastrointestinal cancer: the right combination","volume":"9","author":"Abdelfatah","year":"2016","journal-title":"Therap. Adv. Gastroenterol."},{"key":"B2","year":"2016"},{"key":"B3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.canlet.2009.02.013","article-title":"Isoform-specific histone deacetylase inhibitors: the next step?","volume":"280","author":"Balasubramanian","year":"2009","journal-title":"Cancer Lett."},{"key":"B4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejmech.2018.12.039","article-title":"Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: an overview","volume":"164","author":"Banerjee","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1021\/jm101373a","article-title":"Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation","volume":"54","author":"Botta","year":"2011","journal-title":"J. Med. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.neuroscience.2018.03.022","article-title":"Effects of class II-selective histone deacetylase inhibitor on neuromuscular function and disease progression in SOD1-ALS mice","volume":"379","author":"Buonvicino","year":"2018","journal-title":"Neuroscience"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1021\/jm4011884","article-title":"Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease","volume":"56","author":"Burli","year":"2013","journal-title":"J. Med. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.4155\/fmc-2016-0117","article-title":"Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases","volume":"8","author":"Chakrabarti","year":"2016","journal-title":"Future Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2147\/CMAR.S183310","article-title":"Robust analysis of novel mRNA-lncRNA cross talk based on ceRNA hypothesis uncovers carcinogenic mechanism and promotes diagnostic accuracy in esophageal cancer","volume":"11","author":"Chen","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s10911-012-9263-3","article-title":"Epigenetics as a therapeutic target in breast cancer","volume":"17","author":"Connolly","year":"2012","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"E2337","DOI":"10.3390\/ijms19082337","article-title":"The therapeutic strategy of HDAC6 inhibitors in Lymphoproliferative disease","volume":"19","author":"Cosenza","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"8635","DOI":"10.1016\/j.bmc.2008.08.003","article-title":"Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222","volume":"16","author":"Di Micco","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"B14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone deacetylase inhibitors: overview and perspectives","volume":"5","author":"Dokmanovic","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"B15","year":"2009"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1158\/1078-0432.CCR-17-0589","article-title":"Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 1","volume":"23","author":"Evans","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: first global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"B19","year":"2005"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene"},{"key":"B21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jmb.2004.02.006","article-title":"Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis","volume":"338","author":"Gregoretti","year":"2004","journal-title":"J. Mol. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nchembio.2134","article-title":"Histone deacetylase 6 structure and molecular basis of catalysis and inhibition","volume":"12","author":"Hai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrg3922","article-title":"Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms","volume":"16","author":"Hughes","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-1804-1_1","article-title":"Cancer epigenetics: an introduction","volume":"1238","author":"Kanwal","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40425-019-0517-0","article-title":"HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics","volume":"7","author":"Laino","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B27","year":"2009"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1016\/j.bmcl.2017.06.033","article-title":"The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6\/8 selectivity","volume":"27","author":"Negmeldin","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.molonc.2012.09.003","article-title":"HDAC inhibitor-based therapies: can we interpret the code?","volume":"6","author":"New","year":"2012","journal-title":"Mol. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s40265-014-0275-8","article-title":"Belinostat: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bbrc.2013.03.059","article-title":"Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells","volume":"434","author":"Qiao","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/cncr.32600","article-title":"Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models","volume":"126","author":"Santiago-O'farrill","year":"2019","journal-title":"Cancer"},{"key":"B34","volume-title":"The PyMOL Molecular Graphics System, v. 2.3.","year":"2019"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1016\/j.biochi.2012.05.012","article-title":"Chromatin-modifying agents in anti-cancer therapy","volume":"94","author":"Seidel","year":"2012","journal-title":"Biochimie"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e3807","DOI":"10.1002\/bmc.3807","article-title":"Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine","volume":"31","author":"Suresh","year":"2017","journal-title":"Biomed. Chromatogr."},{"key":"B37","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/cmdc.201300413","article-title":"Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next","volume":"9","author":"Thaler","year":"2014","journal-title":"ChemMedChem"},{"key":"B38","doi-asserted-by":"publisher","first-page":"11262","DOI":"10.1038\/ncomms11262","article-title":"Insights into the activation mechanism of class I HDAC complexes by inositol phosphates","volume":"7","author":"Watson","year":"2016","journal-title":"Nat. Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"20170105","DOI":"10.1098\/rsif.2017.0105","article-title":"Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape","volume":"14","author":"Wenbo","year":"2017","journal-title":"J. R. Soc. Interface"},{"key":"B40","doi-asserted-by":"publisher","first-page":"617","DOI":"10.21873\/anticanres.12266","article-title":"Dual role of mitophagy in cancer drug resistance","volume":"38","author":"Yan","year":"2018","journal-title":"Anticancer Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.2165\/11207170-000000000-00000","article-title":"Romidepsin in the treatment of T-cell lymphoma","volume":"71","author":"Yang","year":"2011","journal-title":"Drugs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","article-title":"HDAC and HDAC inhibitor: from cancer to cardiovascular diseases","volume":"52","author":"Yoon","year":"2016","journal-title":"Chonnam Med. J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/hepr.12757","article-title":"Histone deacetylases function as novel potential therapeutic targets for cancer","volume":"47","author":"Zhang","year":"2017","journal-title":"Hepatol. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"17415","DOI":"10.1002\/chem.201502543","article-title":"Fluorescent coumarin-artemisinin conjugates as mitochondria-targeting theranostic probes for enhanced anticancer activities","volume":"21","author":"Zhang","year":"2015","journal-title":"Chemistry"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1021\/acschemneuro.8b00729","article-title":"How does chirality determine the selective inhibition of histone deacetylase 6? A lesson from trichostatin a enantiomers based on molecular dynamics","volume":"10","author":"Zhang","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ejmech.2018.03.002","article-title":"Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors","volume":"150","author":"Zhao","year":"2018","journal-title":"Eur. J. Med. Chem."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fchem.2020.00256\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T05:32:28Z","timestamp":1586928748000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fchem.2020.00256\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":46,"alternative-id":["10.3389\/fchem.2020.00256"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2020.00256","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"article-number":"256"}}